BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 23471305)

  • 41. Timing effects of combined radioimmunotherapy and radiotherapy on a human solid tumor in nude mice.
    Sun LQ; Vogel CA; Mirimanoff RO; Coucke P; Slosman DO; Mach JP; Buchegger F
    Cancer Res; 1997 Apr; 57(7):1312-9. PubMed ID: 9102219
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Radioimmunotherapy for hematopoietic cell transplantation.
    Jurcic JG
    Immunotherapy; 2013 Apr; 5(4):383-94. PubMed ID: 23557421
    [TBL] [Abstract][Full Text] [Related]  

  • 43. High-dose radioimmunotherapy combined with extracorporeal depletion in a syngeneic rat tumor model: evaluation of toxicity, therapeutic effect, and tumor model.
    Mårtensson L; Nilsson R; Ohlsson T; Sjögren HO; Strand SE; Tennvall J
    Cancer; 2010 Feb; 116(4 Suppl):1043-52. PubMed ID: 20127949
    [TBL] [Abstract][Full Text] [Related]  

  • 44. 131I anti-CD45 radioimmunotherapy effectively targets and treats T-cell non-Hodgkin lymphoma.
    Gopal AK; Pagel JM; Fromm JR; Wilbur S; Press OW
    Blood; 2009 Jun; 113(23):5905-10. PubMed ID: 19332764
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Radioimmunotherapy of nude mice bearing a human interleukin 2 receptor alpha-expressing lymphoma utilizing the alpha-emitting radionuclide-conjugated monoclonal antibody 212Bi-anti-Tac.
    Hartmann F; Horak EM; Garmestani K; Wu C; Brechbiel MW; Kozak RW; Tso J; Kosteiny SA; Gansow OA; Nelson DL
    Cancer Res; 1994 Aug; 54(16):4362-70. PubMed ID: 8044783
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Radioimmunotherapy of head and neck cancer xenografts using 131I-labeled antibody L19-SIP for selective targeting of tumor vasculature.
    Tijink BM; Neri D; Leemans CR; Budde M; Dinkelborg LM; Stigter-van Walsum M; Zardi L; van Dongen GA
    J Nucl Med; 2006 Jul; 47(7):1127-35. PubMed ID: 16818947
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Benefits of combined radioimmunotherapy and anti-angiogenic therapy in a liver metastasis model of human colon cancer cells.
    Li XF; Kinuya S; Yokoyama K; Koshida K; Mori H; Shiba K; Watanabe N; Shuke N; Michigishi T; Tonami N
    Eur J Nucl Med Mol Imaging; 2002 Dec; 29(12):1669-74. PubMed ID: 12458402
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Conditioning with α-emitter based radioimmunotherapy in canine allogeneic hematopoietic cell transplantation.
    Kornblit B; Chen Y; Sandmaier BM
    Chimerism; 2012; 3(2):40-2. PubMed ID: 22772070
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Auger electron radioimmunotherapeutic agent specific for the CD123+/CD131- phenotype of the leukemia stem cell population.
    Leyton JV; Hu M; Gao C; Turner PV; Dick JE; Minden M; Reilly RM
    J Nucl Med; 2011 Sep; 52(9):1465-73. PubMed ID: 21816968
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Targeting strategies for cancer radiotherapy.
    Buchsbaum DJ; Rogers BE; Khazaeli MB; Mayo MS; Milenic DE; Kashmiri SV; Anderson CJ; Chappell LL; Brechbiel MW; Curiel DT
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3048s-3055s. PubMed ID: 10541342
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Quantitative single-particle digital autoradiography with α-particle emitters for targeted radionuclide therapy using the iQID camera.
    Miller BW; Frost SH; Frayo SL; Kenoyer AL; Santos E; Jones JC; Green DJ; Hamlin DK; Wilbur DS; Fisher DR; Orozco JJ; Press OW; Pagel JM; Sandmaier BM
    Med Phys; 2015 Jul; 42(7):4094-105. PubMed ID: 26133610
    [TBL] [Abstract][Full Text] [Related]  

  • 52. α-particle therapy for synovial sarcoma in the mouse using an astatine-211-labeled antibody against frizzled homolog 10.
    Li HK; Sugyo A; Tsuji AB; Morokoshi Y; Minegishi K; Nagatsu K; Kanda H; Harada Y; Nagayama S; Katagiri T; Nakamura Y; Higashi T; Hasegawa S
    Cancer Sci; 2018 Jul; 109(7):2302-2309. PubMed ID: 29952132
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Enhanced efficacy of 90Y-radiolabeled anti-Lewis Y humanized monoclonal antibody hu3S193 and paclitaxel combined-modality radioimmunotherapy in a breast cancer model.
    Kelly MP; Lee FT; Smyth FE; Brechbiel MW; Scott AM
    J Nucl Med; 2006 Apr; 47(4):716-25. PubMed ID: 16595507
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Bismuth 213-labeled anti-CD45 radioimmunoconjugate to condition dogs for nonmyeloablative allogeneic marrow grafts.
    Sandmaier BM; Bethge WA; Wilbur DS; Hamlin DK; Santos EB; Brechbiel MW; Fisher DR; Storb R
    Blood; 2002 Jul; 100(1):318-26. PubMed ID: 12070043
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Combined modality radioimmunotherapy with Taxol and 90Y-Lym-1 for Raji lymphoma xenografts.
    O'Donnell RT; DeNardo SJ; Miers LA; Kukis DL; Mirick GR; Kroger LA; DeNardo GL
    Cancer Biother Radiopharm; 1998 Oct; 13(5):351-61. PubMed ID: 10851425
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Selective radiation of hematolymphoid tissue delivered by anti-CD45 antibody.
    Matthews DC; Badger CC; Fisher DR; Hui TE; Nourigat C; Appelbaum FR; Martin PJ; Bernstein ID
    Cancer Res; 1992 Mar; 52(5):1228-34. PubMed ID: 1531324
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Systemic radioimmunotherapy using a monoclonal antibody, anti-Tac directed toward the alpha subunit of the IL-2 receptor armed with the alpha-emitting radionuclides (212)Bi or (211)At.
    Wesley JN; McGee EC; Garmestani K; Brechbiel MW; Yordanov AT; Wu C; Gansow OA; Eckelman WC; Bacher JD; Flynn M; Goldman CK; MacLin M; Schwartz UP; Jackson-White T; Phillip CM; Decker J; Waldmann TA
    Nucl Med Biol; 2004 Apr; 31(3):357-64. PubMed ID: 15028248
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Radioimmunotherapy with astatine-211 using chimeric monoclonal antibody U36 in head and neck squamous cell carcinoma.
    Cheng J; Ekberg T; Engström M; Nestor M; Jensen HJ; Tolmachev V; Anniko M
    Laryngoscope; 2007 Jun; 117(6):1013-8. PubMed ID: 17440426
    [TBL] [Abstract][Full Text] [Related]  

  • 59. 211At radioimmunotherapy of subcutaneous human ovarian cancer xenografts: evaluation of relative biologic effectiveness of an alpha-emitter in vivo.
    Bäck T; Andersson H; Divgi CR; Hultborn R; Jensen H; Lindegren S; Palm S; Jacobsson L
    J Nucl Med; 2005 Dec; 46(12):2061-7. PubMed ID: 16330571
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Combined modality radioimmunotherapy. Promise and peril.
    Burke PA; DeNardo SJ; Miers LA; Kukis DL; DeNardo GL
    Cancer; 2002 Feb; 94(4 Suppl):1320-31. PubMed ID: 11877763
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.